Fibrodysplasia ossificans progressiva emerges from obscurity.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] Conflict of interest statement: Declaration of interests F.S.K. is a clinical trial investigator for Ashibio, Incyte, Ipsen, and Regeneron; a coinventor of a US patent (pending) to the Trustees of the University of Pennsylvania on the use of MMP-9 inhibitors for heterotopic ossification; and a member of the Medical Registry Advisory Board of the IFOPA. E.M.S. declares no competing interests. R.J.P. is a clinical trial investigator for Ashibio, Incyte, Ipsen, and Regeneron; a coinventor of U.S. patent (pending) to the Trustees of the University of Pennsylvania on the use of MMP-9 inhibitors for heterotopic ossification; a member of the Medical Registry Advisory Board of the IFOPA; and a consultant for Incyte, Ipsen, and Regeneron. 10. Semin Musculoskelet Radiol. 2010 Jun;14(2):201-16. doi: 10.1055/s-0030-1253161. Epub 2010 May 18. The imaging of myositis ossificans. Tyler P(1), Saifuddin A. Author information: (1)Department of Radiology, The Royal National Orthopaedic Hospital, Middlesex, United Kingdom. Myositis ossificans (MO) is characterized by abnormal heterotopic bone formation involving striated muscle, tendons, ligaments, fasciae, and aponeuroses. Myocardium, the diaphragm, tongue, larynx, smooth muscle, and sphincters are all spared. Several subtypes of myositis ossificans exist: posttraumatic myositis ossificans (PTMO), nontraumatic/pseudomalignant myositis ossificans, and myositis ossificans progressiva (MOP). This article reviews the clinical features and differential diagnoses of each subtype of MO and illustrates the typical imaging features demonstrated by plain radiography, ultrasound, radionuclide bone scans, computed tomography, and magnetic resonance imaging. DOI: 10.1055/s-0030-1253161